TD Cowen on Avalo Therapeutics (AVTX): 'Risk/Reward Skewed To Significant Upside For AVTX-009 Phase II'
Tweet Send to a Friend
(Updated - February 24, 2026 9:14 AM EST)
TD Cowen analyst Stacy Ku reiterated a Buy rating on Avalo ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
TD Cowen analyst Stacy Ku reiterated a Buy rating on Avalo ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
